Evidence map›Paper›PMID 30606047›Full record

ArticleThe American journal of psychiatry2019

Neurofunctional Domains Derived From Deep Behavioral Phenotyping in Alcohol Use Disorder.

Laura E Kwako, Melanie L Schwandt, Vijay A Ramchandani, Nancy Diazgranados, George F Koob, Nora D Volkow, Carlos Blanco, David Goldman

Erratum issued 2 registry-linked trialsAbstract read
In one paragraph

Article in The American journal of psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 86 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02231840 recruitingnot on this map

NIAAA Natural History Protocol

TypeobservationalSponsorNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Ran2015 to 2044Enrolled7,500ConditionsAlcohol Use Disorder
NCT04946851 enrolling by invitationnot on this mapstarted 2021, after this paper: background citation

Addictions Neuroclinical Assessment

TypeobservationalSponsorNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Ran2021 to 2031Enrolled1,400ConditionsNormal Physiology, Alcohol Use Disorder
3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Drawbacks to Strengthening Neural Salience Encoding: A Link Between Cortisol and Risky Drinking.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024
    Trial
  6. Trial
  7. Genetically influenced externalizing and internalizing risk pathways as novel prevention targets.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2022
    Trial
  8. Trial
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Laura E KwakoOffice of the Clinical Director, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Bethesda (Kwako, Schwandt, Diazgranados, Goldman); Section on Human Psychopharmacology, NIAAA, Bethesda (Ramchandani); Office of the Director, NIAAA, Bethesda (Koob); Office of the Director, NIDA, Bethesda (Volkow); Division of Epidemiology, Services, and Prevention, NIDA, Bethesda (Blanco); and Laboratory of Neurogenetics, NIAAA, Bethesda (Goldman).
Melanie L SchwandtOffice of the Clinical Director, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Bethesda (Kwako, Schwandt, Diazgranados, Goldman); Section on Human Psychopharmacology, NIAAA, Bethesda (Ramchandani); Office of the Director, NIAAA, Bethesda (Koob); Office of the Director, NIDA, Bethesda (Volkow); Division of Epidemiology, Services, and Prevention, NIDA, Bethesda (Blanco); and Laboratory of Neurogenetics, NIAAA, Bethesda (Goldman).
Vijay A RamchandaniOffice of the Clinical Director, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Bethesda (Kwako, Schwandt, Diazgranados, Goldman); Section on Human Psychopharmacology, NIAAA, Bethesda (Ramchandani); Office of the Director, NIAAA, Bethesda (Koob); Office of the Director, NIDA, Bethesda (Volkow); Division of Epidemiology, Services, and Prevention, NIDA, Bethesda (Blanco); and Laboratory of Neurogenetics, NIAAA, Bethesda (Goldman).
Nancy DiazgranadosOffice of the Clinical Director, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Bethesda (Kwako, Schwandt, Diazgranados, Goldman); Section on Human Psychopharmacology, NIAAA, Bethesda (Ramchandani); Office of the Director, NIAAA, Bethesda (Koob); Office of the Director, NIDA, Bethesda (Volkow); Division of Epidemiology, Services, and Prevention, NIDA, Bethesda (Blanco); and Laboratory of Neurogenetics, NIAAA, Bethesda (Goldman).
George F KoobOffice of the Clinical Director, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Bethesda (Kwako, Schwandt, Diazgranados, Goldman); Section on Human Psychopharmacology, NIAAA, Bethesda (Ramchandani); Office of the Director, NIAAA, Bethesda (Koob); Office of the Director, NIDA, Bethesda (Volkow); Division of Epidemiology, Services, and Prevention, NIDA, Bethesda (Blanco); and Laboratory of Neurogenetics, NIAAA, Bethesda (Goldman).
Nora D VolkowOffice of the Clinical Director, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Bethesda (Kwako, Schwandt, Diazgranados, Goldman); Section on Human Psychopharmacology, NIAAA, Bethesda (Ramchandani); Office of the Director, NIAAA, Bethesda (Koob); Office of the Director, NIDA, Bethesda (Volkow); Division of Epidemiology, Services, and Prevention, NIDA, Bethesda (Blanco); and Laboratory of Neurogenetics, NIAAA, Bethesda (Goldman).
Carlos BlancoOffice of the Clinical Director, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Bethesda (Kwako, Schwandt, Diazgranados, Goldman); Section on Human Psychopharmacology, NIAAA, Bethesda (Ramchandani); Office of the Director, NIAAA, Bethesda (Koob); Office of the Director, NIDA, Bethesda (Volkow); Division of Epidemiology, Services, and Prevention, NIDA, Bethesda (Blanco); and Laboratory of Neurogenetics, NIAAA, Bethesda (Goldman).
David GoldmanOffice of the Clinical Director, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Bethesda (Kwako, Schwandt, Diazgranados, Goldman); Section on Human Psychopharmacology, NIAAA, Bethesda (Ramchandani); Office of the Director, NIAAA, Bethesda (Koob); Office of the Director, NIDA, Bethesda (Volkow); Division of Epidemiology, Services, and Prevention, NIDA, Bethesda (Blanco); and Laboratory of Neurogenetics, NIAAA, Bethesda (Goldman).

Funding

Neurobiology of Substance Abuse and AddictionZIAAA000550 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI VOLKOW, NORA D. · 2009 to 2025
$115.1M
Integrative genetics of behavior with high throughput technologiesZIAAA000301 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI GOLDMAN, DAVID · 2009 to 2025
$68.6M
NIAAA Repository/Screening Database Management and ResearchZIAAA000130 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI SCHWANDT, MELANIE · 2017 to 2025
$60.1M
Alcohol Pharmacokinetics and Pharmacodynamics in HumansZIAAA000466 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI RAMCHANDANI, VIJAY ARJUN · 2009 to 2025
$31.2M
Intramural NIH HHS Z99 AA999999
6 · The paper itself

Abstract

objectiveThe authors evaluated whether three neurofunctional domains proposed to be critical in the addiction cycle, namely, incentive salience, negative emotionality, and executive function, could be identified through factor analysis of a deeply phenotyped clinical sample.

methodsClinical, behavioral, and self-report measures of addiction, personality, cognition, behavior, and exposure to early-life stress were collected as part of a screening and natural history study of alcohol use disorders in 454 individuals representing the spectrum of alcohol use and use disorders. The multiple indicators, multiple causes (MIMIC) approach was used to identify significant predictors of the latent factors identified by the analysis.

resultsThe results showed significant support for both three- and four-factor models to explain biobehavioral variation in this sample of participants with alcohol use disorder and control subjects, but the three-factor model had the best fit indices. With some nuances, including cross-correlation (lack of independence) between the three factors, the factors corresponded to incentive salience, negative emotionality, and executive function (executive control). The MIMIC model revealed that both exposure to early-life stress and sociodemographic variables predicted these factors.

conclusionsThese findings suggest that three correlated neurofunctional domains are relevant for alcohol use disorder. More work is required to validate and standardize measures of neurofunctional domains in alcohol use disorder, to extend these findings to other addictive disorders, and to relate variations in them to predisposition, clinical course, treatment response, neuroimaging data, and other psychophysical indicators.

Indexed as

AdultAlcoholismBehavior, AddictiveCase-Control StudiesEmotionsExecutive FunctionFemaleHumansMaleMiddle AgedModels, PsychologicalMotivationNeuropsychological TestsPhenotypePsychological TestsRisk FactorsAlcohol AbuseCognitive NeuroscienceModels/Theories Of Psychiatry

Identifiers

PMID30606047
PMCPMC6609498

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.